The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter I: Current practice and remaining unmet medical needs

Regenerative Medicine

Volumn 10, Issue 3, 2015, Pages 331-343

  Vertès, Alain A ^a,b  

^a LONDON BUSINESS SCHOOL   (United Kingdom)

^b NxR Biotechnologies GmbH   (Switzerland)

Author keywords

graft versus host disease; GvHD; GvHD market estimate; hematopoietic stem cells; mesenchymal stem cells; NK cells; transplantation; Treg cells

Indexed keywords

ANTIFUNGAL AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; INFLIXIMAB; MYCOPHENOLATE MOFETIL; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; CELLULAR IMMUNITY; CLINICAL PRACTICE; CORD BLOOD STEM CELL TRANSPLANTATION; COST EFFECTIVENESS ANALYSIS; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEALTH CARE COST; HEALTH CARE NEED; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LENGTH OF STAY; MORTALITY; NONMYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED INTENSITY CONDITIONING; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SURVIVAL RATE; ANIMAL; BIOLOGICAL THERAPY; CONVALESCENCE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; PROCEDURES;

ANEMIA; ANIMALS; CELL- AND TISSUE-BASED THERAPY; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; RECOVERY OF FUNCTION;

EID: 84930009212     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.15.12     Document Type: Review

References (127)

1. Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N. Engl. J. Med. 257, 491-496 (1957).
2. Thomas ED, Fefer A, Buckner CD, Storb R. Current status of bone marrow transplantation for aplastic anemia and acute leukemia. Blood 49, 671-681 (1977).
3. Storb R, Thomas ED, Weiden PL et al. Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle. Blood 48, 817-841 (1976).
4. Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat. Rev. Cancer 10, 213-221 (2010).
5. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 373, 1550-1561 (2009).
6. Gratwohl A, Baldomero H, Horisberger B et al. Current trends in hematopoietic stem cell transplantation in Europe. Blood 100, 2374-2386 (2002).
7. Copelan EA. Hematopoietic stem-cell transplantation. N. Engl. J. Med. 354, 1813-1826 (2006).
8. Little MT, Storb R. History of haematopoietic stem-cell transplantation. Nat. Rev. Cancer 2, 231-238 (2002).
9. Appelbaum FR. Hematopoietic-cell transplantation at 50. N. Engl. J. Med. 357, 1472-1475 (2007).
10. Hobbs JR. Bone marrow transplantation for inborn errors. Lancet 2, 735-739 (1981).
11. Hoogerbrugge PM, Brouwer OF, Bordigoni P et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet 345, 1398-1402 (1995).
12. Li HW, Sykes M. Emerging concepts in haematopoietic cell transplantation. Nat. Rev. Immunol. 12, 403-416 (2012).
13. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112, 4371-4383 (2008).
14. Ferrara JL. Novel strategies for the treatment and diagnosis of graft-versus-host-disease. Best Pract. Res. Clin. Haematol. 20, 91-97 (2007).
15. Bernardo ME, Ball LM, Cometa AM et al. Co-infusion of ex vivo-expanded, parental MSCs prevents life-Threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant. 46, 200-207 (2011).
16. Choi SW, Reddy P. Current and emerging strategies for the prevention of graft-versus-host disease. Nat. Rev. Clin. Oncol. 11, 536-547 (2014).
17. Gratwohl A, Niederwieser D. History of hematopoietic stem cell transplantation: evolution and perspectives. Transplant. Dermatol.43, 81-90 (2012).
18. Barton-Burke M, Dwinell DM, Kafkas L et al. Graft-versushost disease: a complex long-Term side effect of hematopoietic stem cell transplant. Oncology (Williston Park) 22, 31-45 (2008).
19. Warren EH, Deeg HJ. Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. Tissue Antigens 81, 183-193 (2013).
20. Sung AD, Chao NJ. Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. Stem Cells Transl. Med. 2, 25-32 (2013).
21. Qian L, Wu Z, Shen J. Advances in the treatment of acute graft-versus-host disease. J. Cell. Mol. Med. 17, 966-975 (2013).
22. Teshima T. Th1 and Th17 join forces for acute GvHD. Blood 118, 4765-4767 (2011).
23. Pan B, Zhang Y, Sun Y et al. Deviated balance between Th1 and Th17 cells exacerbates acute graft-versus-host disease in mice. Cytokine 68, 69-75 (2014).
24. Coghill JM, Sarantopoulos S, Moran TP, Murphy WJ, Blazar BR, Serody JS. Effector CD4+ T cells, the cytokines they generate, and GvHD: something old and something new. Blood 117, 3268-3276 (2011).
25. Eapen M, Horowitz MM, Klein JP et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J. Clin. Oncol. 22, 4872-4880 (2004).
26. Berenson RJ, Andrews RG, Bensinger WI et al. Antigen CD34+ marrow cells engraft lethally irradiated baboons. J. Clin. Invest. 81, 951-955 (1988).
27. Molineux G, Pojda Z, Hampson IN, Lord BI, Dexter TM. Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood 76, 2153-2158 (1990).
28. Hoggatt J, Pelus LM. Many mechanisms mediating mobilization: an alliterative review. Curr. Opin. Hematol. 18, 231-238 (2011).
29. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colonystimulating factor. Blood 85, 1655-1658 (1995).
30. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 85, 1666-1672 (1995).
31. Ringden O, Remberger M, Runde V et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 94, 455-464 (1999).
32. Milone G, Martino M, Spadaro A et al. Plerixafor ondemand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br. J. Haematol. 164, 113-123 (2014).
33. Duarte RF, Shaw BE, Marín P et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant. 46, 52-58 (2011).
34. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N. Engl. J. Med. 344, 175-181 (2001).
35. Couban S, Simpson DR, Barnett MJ et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100, 1525-1531 (2002).
36. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-Analysis. J. Clin. Oncol. 19, 3685-3691 (2001).
37. Storek J, Gooley T, Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 90, 4705-4709 (1997).
38. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden O. Increased risk of extensive chronic graft-versushost disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 105, 548-551 (2005).
39. Pasquini M, Wang Z, Schneider L. CIBMTR summary slides CIBMTR Newsletter 13, 2-9 (2007). www.cibmtr.org
40. Howe CWS, Radde-Stepaniak T. Hematopoietic cell donor registries. In: Hematopoietic Cell Transplantation (2nd Edition). Thomas ED, Blume KG, Forman SJ, Malden MA (Eds). Blackwell Science, Oxford, England, 503-512 (1999).
41. Barker JN, Krepski TP, DeFor TE, Davies SM, Wagner JE, Weisdorf DJ. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol. Blood Marrow Transplant. 8, 257-260 (2002).
42. Gluckman E. History of cord blood transplantation. Bone Marrow Transplant. 44, 621-626 (2009).
43. Broxmeyer HE, Gordon GW, HAngoc G et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc. Natl Acad. Sci. USA 86, 3828-3832 (1989).
44. Querol S, Mufti GJ, Marsh SG et al. Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be? Haematologica 94, 536-541 (2009).
45. Han P, Hodge G, Story C, Xu X. Phenotypic analysis of functional T-lymphocyte subtypes and natural killer cells in human cord blood: relevance to umbilical cord blood transplantation. Br. J. Haematol. 89, 733-740 (1995).
46. Godfrey WR, Spoden DJ, Ge YG et al. Cord blood CD4(+) CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 105, 750-758 (2005).
47. Gluckman E. Current status of umbilical cord blood hematopoietic stem cell transplantation. Exp. Hematol. 28, 1197-1205 (2000).
48. Kollman C, Abella E, Baitty RL et al. Assessment of optimal size and composition of the US National Registry of hematopoietic stem cell donors. Transplantation 78, 89-95 (2004).
49. Barker JN, Rocha V, Scaradavou A. Optimizing unrelated donor cord blood transplantation. Biol. Blood Marrow Transplant. 15, 154-161 (2009).
50. Barker JN, Weisdorf DJ, Wagner JE. Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. N. Engl. J. Med. 344, 1870-1871 (2001).
51. Barker JN, Weisdorf DJ, DeFor TE et al. Transplantation of 2 partially HLA matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105, 1343-1347 (2005).
52. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood 122, 491-498 (2013).
53. Kanakry CG, Fuchs EJ. Studies comparing haploidentical and cord blood transplantation. In: Umbilical Cord Blood Banking and Transplantation. Ballen K (Ed.). Springer, Cham, Switzerland, 221-234 (2014).
54. Oevermann L, Handgretinger R. New strategies for haploidentical transplantation. Pediatr. Res. 71, 418-426 (2012).
55. Luznik L, O'Donnell PV, Symons HJ et al. HLAhaploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 14, 641-650 (2008).
56. O'Donnell PV, Luznik L, Jones RJ et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 8, 377-386 (2002).
57. Raiola AM, Dominietto A, Ghiso A et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol. Blood Marrow Transplant. 19, 117-122 (2013).
58. Piemontese S, Ciceri F, Labopin M et al. A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. Leukemia doi:10.1038/leu.2014.336 (2014) (Epub ahead of print).
59. Petersdorf EW, Gooley TA, Anasetti C et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 92, 3515-3520 (1998).
60. Petersdorf EW, Anasetti C, Martin PJ et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 104, 2976-2980 (2004).
61. Laughlin MJ, Eapen M, Rubinstein P et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N. Engl. J. Med. 351, 2265-2275 (2004).
62. Gratwohl A et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematology. 2(3), e91-e100 (2015).
63. Gratwohl A, Baldomero H, Aljurf M et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 303, 1617-1624 (2010).
64. Gratwohl A, Baldomero H, Passweg J. Hematopoietic stem cell transplantation activity in Europe. Curr. Opin. Hematol. 20, 485-493 (2013).
65. Yoshimi A, Suzuki R, Atsuta Y et al. Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group. Bone Marrow Transplant. 45, 1682-1691 (2010).
66. Bone Marrow Donors Worldwide. www.bmdw.org/
67. Ball LM, Egeler RM. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant. 41(Suppl. 2), S58-S64 (2008)
68. Gratwohl A, Niederwieser D. History of hematopoietic stem cell transplantation: evolution and perspectives. Curr. Probl. Dermatol. 43, 81-90 (2012).
69. Graft Versus Host Disease (GvHD) Therapeutics-Pipeline Assessment and Market Forecasts to 2018. London, UK. GlobalData (2012).
70. Stakeholder Opinions: Hematopoietic Stem Cell Transplantation (HSCT): in need of further research and development. Datamonitor. www.datamonitor.com/
71. Ram R, Gafter-Gvili A, Yeshurun M, Paul M, Raanani P, Shpilberg O. Prophylaxis regimens for GVHD: systematic review and meta-Analysis. Bone Marrow Transplant. 43, 643-653 (2009).
72. Messina C, Faraci M, de Fazio V, Dini G, Calo MP, Calore E. Prevention and treatment of acute GvHD. Bone Marrow Transplant. 41(Suppl. 2), S65-S70 (2008).
73. Shpilberg O, Herscovici C, Dreyer J et al. Cannabidiol-An innovative strategy for graft versus host disease prevention. Blood 122, 3299 (2013).
74. Jacobsohn DA. Acute graft-versus-host disease in children. Bone Marrow Transplant. 41, 215-221 (2008).
75. Arai S, Jagasia M, Storer B et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 118, 4242-4249 (2011).
76. Prasad VK, Lucas KG, Kleiner GI et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol. Blood Marrow Transplant. 17, 534-541 (2011).
77. Jacobsohn DA. Optimal management of chronic graftversus-host disease in children. Br. J. Haematol. 150, 278-292 (2010).
78. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin. Hematol. 43, 3-10 (2006).
79. Ghosh A, Holland AM, van den Brink MR. Genetically engineered donor T cells to optimize graft-versus-Tumor effects across MHC barriers. Immunol. Rev. 257, 226-236 (2014).
80. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N. Engl. J. Med. 304, 1529-1533 (1981).
81. Passweg JR, Tiberghien P, Cahn JY et al. Graft-versusleukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant. 21, 153-158 (1998).
82. Horowitz MM, Gale RP, Sondel PM et al. Graft-versusleukemia reactions after bone marrow transplantation. Blood 75, 555-562 (1990).
83. Champlin RE, Passweg JR, Zhang MJ et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 95, 3996-4003 (2000).
84. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78, 2120-2130 (1991).
85. Henslee-Downey PJ, Abhyankar SH, Parrish RS et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 89, 3864-3872 (1997).
86. Ringden O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A,-B and-DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant. 15, 619-625 (1995).
87. Socié G, Schmoor C, Bethge WA et al. Chronic graft-versushost disease: long-Term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-Tcell globulin ATG-Fresenius. Blood 117, 6375-6382 (2011).
88. Theurich S, Fischmann H, Chakupurakal G et al. Antithymocyte globulins for post-Transplant graft-versus-host disease prophylaxis-A systematic review and meta-Analysis. Crit. Rev. Oncol. Hematol. 88, 178-186 (2013).
89. Bacigalupo A, Lamparelli T, Barisione G et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: longterm follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol. Blood Marrow Transplant. 12, 560-565 (2006).
90. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant. 35, 225-231 (2005).
91. Remberger M, Svahn BM, Mattsson J, Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 78, 122-127 (2004).
92. Cutler C, Logan B, Nakamura R et al. Tacrolimus/sirolimus versus tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic hematopoietic cell transplantation. Blood 124(8), 1372-1377 (2014).
93. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graftversus-host disease in patients given HLA-identical marrow grafts for leukemia: long-Term follow-up of a controlled trial. Blood 73, 1729-1734 (1989).
94. Storb R, Thomas ED. Graft-versus-host disease in dog and man: the Seattle experience. Immunol. Rev. 88, 215-238 (1985).
95. MacMillan ML, Defor TE, Weisdorf DJ. What predicts high risk acute graft-versus-host disease (GvHD) at onset? Identification of those at highest risk by a novel acute GvHD risk score. Br. J. Haematol. 157, 732-741 (2012).
96. MacMillan ML, Weisdorf DJ, Wagner JE et al. Response of 443 patients to steroids as primary therapy for acute graftversus-host disease: comparison of grading systems. Biol. Blood Marrow Transplant. 8, 387-394 (2002).
97. Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/ severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 75, 1024-1030 (1990).
98. Westin JR, Saliba RM, De Lima M et al. Steroid-refractory acute GVHD. Predictors and outcomes. Adv. Hematol. 2011, 601953 (2011).
99. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18, 295-304 (1974).
100. Fowler DH. Shared biology of GVHD and GVT effects: potential methods of separation. Crit. Rev. Oncol. Hematol. 57, 225-244 (2006).
101. Rezvani AR, Storb RF. Separation of graft-vs.-Tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation. J. Autoimmun. 30, 172-179 (2008).
102. Shlomchik WD. Graft-versus-host disease. Nat. Rev. Immunol. 7, 340-352 (2007).
103. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant. Registry. Bone Marrow Transplant. 17(Suppl. 3), S5-S6 (1996).
104. Stewart BL, Storer B, Storek J et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 104, 3501-3506 (2004).
105. Jagasia M, Greinix H, Robin M et al. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol. Blood Marrow Transplant. 19, 1129-1133 (2013).
106. Xhaard A, Rocha V, Bueno B et al. Steroid-refractory acute GVHD: lack of long-Term improved survival using new generation anticytokine treatment. Biol. Blood Marrow Transplant. 18, 406-413 (2012).
107. Ananda-Rajah MR, Cheng A, Morrissey CO et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. Antimicrob. Agents Chemother. 55, 1953-1960 (2011).
108. Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood 120, 1545-1551 (2012).
109. Flomenberg N, Baxter-Lowe LA, Confer D et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104, 1923-1930 (2004).
110. Devetten M, Armitage JO. Hematopoietic cell transplantation: progress and obstacles. Ann. Oncol. 18, 1450-1456 (2007).
111. Cutler C, Antin JH. Novel drugs for the prevention and treatment of acute GVHD. Curr. Pharm. Des. 14, 1962-1973 (2008).
112. Ho VT, Cutler C. Current and novel therapies in acute GVHD. Best Pract. Res. Clin. Haematol. 21, 223-237 (2008).
113. Harris AC, Ferrara JL, Braun TM et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 119, 2960-2963 (2012).
114. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood 115, 5412-5417 (2010).
115. Svahn BM, Ringden O, Remberger M. Treatment costs and survival in patients with grades III-IV acute graftversus-host disease after allogenic hematopoietic stem cell transplantation during three decades. Transplantation 81, 1600-1603 (2006).
116. Prather W. Pluristem Therapeutics, Inc. Regen. Med. 3, 117-122 (2008).
117. Fierce Biotech. Dendreon: Provenge to cost $93K for full course of treatment. www.fiercebiotech.com/story/dendreonprovenge-cost-93k-full-course-Treatment/2010-04-29
118. Vertes AA. Deciphering the therapeutic stem cell strategies of large and midsize pharmaceutical firms. Regen. Med. 9, 479-495 (2014).
119. Vertes AA, Qureshi N, Caplan AI, Babiss L. Stem Cells in Regenerative Medicine: Science, Regulation, and Business Strategies. Wiley, Chichester, UK (2015).
120. Qasim W, Thrasher AJ. Progress and prospects for engineered T cell therapies. Br. J. Haematol. 166, 818-829 (2014).
121. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 13, 392-402 (2013).
122. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu. Rev. Pathol. 6, 457-478 (2011).
123. Metheny L, Caimi P, de Lima M. Cord blood transplantation: can we make it better? Front. Oncol. 3, 228 (2013).
124. Battiwalla M, Barrett AJ. Bone marrow mesenchymal stromal cells to treat complications following allogeneic stem cell transplantation. Tissue Eng. Part B Rev. 20, 211-217 (2014).
125. Amorin B, Alegretti AP, Valim V et al. Mesenchymal stem cell therapy and acute graft-versus-host disease: a review. Hum. Cell. 27, 137-150 (2014).
126. Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81, 1390-1397 (2006).
127. Vertes AA. The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graftversus-host disease. Chapter II: Emerging transformational cytotherapies. Regen. Med. 10(3) 345-373 (2015).